罗格列酮对2型糖尿病合并冠心病患者血清基质金属蛋白酶-9及高敏C-反应蛋白的影响

Effect of rosiglitazone treatment on MMP-9 and high-sensitivity C-reactive protein in the patients with type 2 diabetes mellitus and coronary artery disease

目的:探讨罗格列酮的抗炎、抗动脉粥样硬化作用及其机制。方法:2型糖尿病合并冠心病患者60例随机分为罗格列酮治疗组和常规治疗组。采用酶联免疫吸附法测定血清基质金属蛋白酶-9、高敏C-反应蛋白水平,观察罗格列酮治疗前后血清基质金属蛋白酶-9、高敏C-反应蛋白水平变化及与常规治疗组之间变化的差别。结果:治疗2周时的血清基质金属蛋白酶-9、高敏C-反应蛋白水平分别较治疗前水平下降,应用罗格列酮治疗组较常规治疗组下降明显,差异有统计学意义(P<0.05)。空腹血糖在2治疗组间差异无统计学意义(P>0.05)。罗格列酮治疗12周时的血清基质金属蛋白酶-9、高敏C-反应蛋白较治疗2周时下降,差异有统计学意义(P<0.05)。结论:罗格列酮具有抗炎及独立于降糖之外的抗动脉粥样硬化作用,且在一定时期内具有时间依赖性。

Objective To investigate the anti-inflammation and anti-atherosclerosis effects of rosiglitazone. Methods Type 2 diabetic patients with coronary artery disease were randomly devided into two groups, with or without rosiglitazone treatment. The serum MMP-9 and high-sensitivity C-reactive protein were determined with ELISA to observe the differences after treatment between the groups. Results The serum MMP-9 and high-sensitivity C reactive protein levels after rosiglitazone treatment for 2 weeks decreaced compared to the baseline. However the changes of fasting plasma glucose in the two groups had no difference. The serum MMP-9 and high-sensitivity C-reactive protein levels were respectively after rosiglitazone treatment for 12 weeks deereaced significantly compared to that for 2 weeks. Conclusion Rosiglitazone has anti-inflammative and anti atherosclerotic effects independent of the lowering blood glucose. And the lowering blood glucose and anti-atherosclerotic effects are depended on time in the periord.